Microbia, Inc. Appoints Dr. Jeffrey M. Johnston As Vice President, Clinical Development And Chief Medical Officer
CAMBRIDGE, Mass., Oct. 20 /PRNewswire/ -- Microbia, Inc. today announced the appointment of Dr. Jeffrey M. Johnston to the position of vice president, clinical development and chief medical officer. In this role, Dr. Johnston will be responsible for all aspects of clinical development and will serve as a member of the Company's senior management team.
"We are extremely pleased to have Jeff join Microbia. His wealth of clinical research experience and pharmaceutical company leadership will enable us to rapidly guide our novel drug candidates through the clinic and into the hands of patients who need them," said Peter Hecht, chief executive officer at Microbia. "With his impressive credentials, including more than 15 years of clinical development experience in both global pharmaceutical and smaller innovative company efforts, Jeff will provide strong direction to our clinical programs."
Dr. Johnston joins Microbia from Critical Therapeutics, where he was chief medical officer and vice president of drug development. Prior to his position at Critical Therapeutics, he was vice president, clinical research at Triangle Pharmaceuticals and spent more than a dozen years in positions of increasing seniority in the clinical development organization at GlaxoSmithKline.
"I am excited to be joining the Microbia team to lead the existing development programs along with what I believe are important clinical candidates emerging from Microbia's research efforts," said Dr. Johnston. "My experience leading clinical research across a broad range of therapeutic areas fits well with Microbia's diverse research and development."
After receiving his medical degree from the Duke University School of Medicine in Durham, N.C., Dr. Johnston completed his internal medicine residency at Vanderbilt University in Nashville, Tenn., and his infectious diseases fellowship at the University of Utah School of Medicine in Salt Lake City. His work has been widely published in peer-reviewed journals.
About Microbia
Microbia (http://www.microbia.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drugmaking. Two of the Company's drug candidates are in clinical studies-MD-1100 for the treatment of constipation-predominant irritable bowel syndrome and other gastrointestinal disorders, and MD-0727 for the treatment of hypercholesterolemia. Our Precision Engineering(TM) business unit collaborates with leading pharmaceutical and chemical manufacturers to improve efficiencies of existing fermentation processes or to create new bioprocesses. Microbia has raised $99 million in private equity financing and is located in Cambridge, Massachusetts.
Corporate Inquiries: Susan Brady Microbia, Inc. (617) 621-8304 sbrady@microbia.com Media Inquiries: Kelly Lindenboom Biosector 2 (212) 845-5622 klindenboom@biosector2.com
Microbia, Inc.CONTACT: Susan Brady of Microbia, Inc., +1-617-621-8304,sbrady@microbia.com; or Kelly Lindenboom of Biosector 2, +1-212-845-5622,klindenboom@biosector2.com
Web site: http://www.microbia.com/